VWR International, Thermo Fisher Sign Global Agreement

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

The deal is being made for an all-cash price of $250 million, but with an additional $752.5 million available in potential milestone payments.

Data from a Phase III study that evaluated lazertinib, in combination with amivantamab, in comparison to osimertinib as a first-line treatment resulted in the EC’s decision.

The company’s investments in Canada since 2023 have now resulted in the creation, or potential thereof, of 1200 new job positions.